Table 1.
Demographic and clinical characteristics of 116 infants receiving palivizumab in 2004–2005
| Mean | Median | Range (min–max) | % | |
|---|---|---|---|---|
| Age at birth (weeks) | 32.2 | 32.3 | 16.4 (24.6–41.0) | |
| Weight at birth (g) | 1919.8 | 1814.0 | 3544 (567–4111) | |
| Age at first palivizumab dose (months) | 5.1 | 3.52 | 35.16 (0.23–35.39) | |
| No. of doses of palivizumab received | 5.7 | 6 | 7 (1–8) | |
| Prematurity <33 weeks | 64.7 | |||
| Prematurity 33–35 weeks + risk factors | 14.7 | |||
| Gender = male | 58.6 | |||
| ≥1 brother or sister in household | 64.6 | |||
| Kindergarten frequentation | 4.3 | |||
| Smokers in household | 20.7 | |||
| Breastfeeding | 39.6 | |||
| Underlying diseases | ||||
| Pulmonary | 24.1 | |||
| Cardiac | 7.8 | |||
| Metabolic/genetic | 6.9 | |||
| Neurologic | 0 | |||
| Previous respiratory infections | ||||
| Bronchiolitis | 12.1 | |||
| Pneumonitis | 8.6 | |||
| Otitis media | 2.6 | |||
| Usual medication | ||||
| Oxygen | 4.3 | |||
| Bronchodilatators | 13.8 | |||
| Steroids | 6.9 | |||
| Cardiac drugs | 4.3 | |||
| Influenza vaccination in 2004–2005 | 31.9 | |||
| Palivizumab in 2003–2004 | 8.9 | |||